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Introduction
Hyaluronan (HA) is a glycosaminoglycan that is broadly dis-
tributed in extracellular spaces (Aruffo et al., 1990). HA is 
especially enriched in pericellular matrices surrounding mi-
grating and proliferating cells during embryonic development, 
tissue repair, and infl  ammation (Fraser et al., 1997). The most 
widely distributed form of HA in normal tissues is a high mo-
lecular weight (HMW) extracellular and cell surface polysac-
charide that usually consists of several million daltons (called 
HMW-HA). HMW-HA forms a highly viscous network that 
is important for molecular exclusion, fl  ow resistance, tissue 
osmosis, lubrication, and hydration. Lower molecular weight 
forms of HA that are synthesized de novo or generated by 
either hyaluronidase-mediated degradation or oxidative hydro-
lysis of HMW-HA may accumulate at sites of infl  ammation 
(Hawkins and Davies, 1998; Noble, 2002). The biological activit-
ies of HMW-HA and the lower molecular weight forms of HA 
are distinct (Cuff et al., 2001; Puré and Cuff, 2001; Noble, 2002).
HMW-HA and lower molecular weight forms of HA in-
fl  uence proliferation, migration, and adhesion of cells within 
matrices by binding to cell surface receptors such as CD44, 
RHAMM, LYVE-1, and layilin (Turley et al., 1987; Banerji 
et al., 1999; Bono et al., 2001). CD44, which is arguably the best 
studied HA receptor, is a type I transmembrane glycoprotein 
encoded by a single gene and expressed as multiple isoforms. 
The structural diversity of CD44 is generated by alternative 
RNA splicing as well as differential posttranslational modifi  -
cations, including glycosylation and the attachment of glycos-
aminoglycans (Brown et al., 1991; Stamenkovic et al., 1991; 
Greenfi  eld et al., 1999). The HA-binding domain is present in 
all isoforms of CD44. We previously reported that HMW-HA 
and a lower molecular weight HA regulate cell cycle progres-
sion through G1 phase in vascular smooth muscle cells (SMCs; 
Cuff et al., 2001). Interestingly, SMCs treated with HMW-HA 
were blocked in G1 phase, whereas the lower molecular form of 
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  H
igh molecular weight (HMW) hyaluronan (HA) 
is widely distributed in the extracellular matrix, 
but its biological activities remain incompletely 
understood. We previously reported that HMW-HA 
  binding to CD44 antagonizes mitogen-induced S-phase 
entry in vascular smooth muscle cells (SMCs; Cuff, C.A., 
D. Kothapalli, I. Azonobi, S. Chun, Y. Zhang, R. Belkin, 
C. Yeh, A. Secreto, R.K. Assoian, D.J. Rader, and E. Puré. 
2001. J. Clin. Invest. 108:1031–1040); we now charac-
terize the underlying molecular mechanism and  document 
its relevance in vivo. HMW-HA inhibits the mitogen-
  dependent induction of cyclin D1 and down-regulation of 
p27
kip1 in vascular SMCs. p27
kip1 messenger RNA levels 
were unaffected by HMW-HA, but the expression of 
Skp2, the rate-limiting component of the SCF complex 
that degrades p27
kip1, was reduced. Rescue experiments 
identiﬁ  ed cyclin D1 as the primary target of HMW-HA. 
Similar results were observed in ﬁ  broblasts, and these 
antimitogenic effects were not detected in CD44-null 
cells. Analysis of arteries from wild-type and CD44-null 
mice showed that the effects of HMW-HA/CD44 on 
  cyclin D1 and Skp2 gene expression are detected in vivo 
and are associated with altered SMC proliferation after 
vascular injury.
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HA (Mr =  2 × 10
5) stimulated progression through G1 phase 
(Cuff et al., 2001). CD44 was required for both of these effects 
(Cuff et al., 2001).
Progression through G1 phase is regulated by cyclin-
  dependent kinases (cdks), cyclin D–cdk4 or cdk6 (hereafter 
called cdk4/6), and cyclin E–cdk2. Once activated, these cdks 
phosphorylate pocket proteins such as Rb (retinoblastoma) 
and p107, leading to the release of E2Fs and E2F-dependent 
gene transcription. E2F regulates several genes that are needed 
for the entry and completion of S phase as well as for further 
cell cycle progression (Dimova and Dyson, 2005). Mitogenic 
stimulation activates cdk4/6 by allowing for the induction of 
at least one member of the cyclin D family (D1, D2, or D3), with 
D1 being a major D-type cyclin in mesenchymal cells such 
as fi  broblasts and vascular SMCs. The mechanisms leading 
to the mitogen-dependent activation of cyclin E–cdk2 are more 
complex, involving decreases in the expression of p21 family 
cdk inhibitors (p21
cip1, p27
kip1, and p57
kip2). p21
cip1 and p27
kip1 
(hereafter called p21 and p27) are the best characterized. 
These inhibitors bind to cyclin E–cdk2 complexes in G0 
and early G1 phases to maintain them in a catalytically in-
active state (Sherr and Roberts, 1999). The down-regulation of 
p21 and p27 in late G1 phase contributes to the late G1-phase 
activation of cyclin E–cdk2. In addition, the p21 family cdk 
inhibitors promote the assembly (Sherr and Roberts, 1999) or 
stability (Bagui et al., 2003) of cyclin D–cdk4/6 complexes 
without inhibiting their catalytic activity. In fact, the mitogen-
dependent induction of cyclin D1 is thought to contribute 
to the activation of cyclin E–cdk2 indirectly by sequestering 
p21/p27 on cyclin D–cdk4/6 complexes and, thereby, pre-
venting p21/p27 from inhibiting cyclin E–cdk2 (Sherr and 
Roberts, 1999).
This study was designed to identify the cell cycle regu-
latory mechanism responsible for the antimitogenic effect of 
HMW-HA in vascular SMCs, to determine the applicability 
of  the mechanism to other mesenchymal cell types, and to 
  assess the relevance of the mechanism during SMC prolifera-
tion in vivo. We conclude that HMW-HA binding to CD44 
  selectively inhibits cyclin D1 expression and p27 degradation 
in both vascular SMCs and fi  broblasts. The effect on cyclin D1 
is primary, whereas the effect on p27 is caused by an HA/ 
cyclin D1–dependent inhibition of Skp2, the rate-limiting 
component of the SCF
Skp2 complex that degrades p27. These 
effects can account for the antimitogenic effect of HMW-HA 
on S-phase entry in vitro, are detected in vivo, and are associ-
ated with increased SMC proliferation after vascular injury in 
CD44-null mice.
Results
HMW-HA inhibits Rb hyperphosphorylation 
and cyclin A expression in human 
vascular SMCs
We previously reported that HMW-HA inhibits the S-phase 
 entry of mouse vascular SMCs (Cuff et al., 2001). A similar anti-
mitogenic effect was detected in early passage human vascular 
SMCs, as determined by BrdU labeling (Fig. 1 A) and fl  ow 
  cytometry (Table I). The effect was dose dependent and was 
largely reversed by anti-CD44 but not by an isotype-matched 
irrelevant antibody (Fig. 1 B). The small antimitogenic HMW-
HA effect remaining in human vascular SMCs treated with neu-
tralizing anti-CD44 may be caused by the actions of alternative 
HA receptors (see Introduction).
Other ECM components with antimitogenic activity (e.g., 
the matricellular proteins thrombospondin, SPARC [secreted 
protein acidic rich in cysteine], and tenascin-C) disassemble fo-
cal adhesions, disrupt actin stress fi  bers, and can also inhibit 
cell spreading (Bradshaw and Sage, 2001; Murphy-Ullrich, 
2001). HMW-HA had none of these effects even under condi-
tions in which it showed its typical inhibitory effect on S-phase 
entry (Fig. 1 C).
Figure 1.  HMW-HA inhibits S-phase entry in human SMCs. (A) Quiescent 
human vascular SMCs were stimulated with 10% FBS for the selected times 
in the absence (control; white bars) or presence (black bars) of 200 μg/ml 
HMW-HA. *, P < 0.001. (B) Quiescent human vascular SMCs were stimu-
lated with 10% FBS for 48 h in the presence of increasing concentrations 
of HMW-HA. A blocking antibody speciﬁ  c for human CD44 (5F12) or 
50 μg/ml of an isotype-matched irrelevant antibody was added to the 
cells at the time of FBS stimulation and remained in the culture for the dura-
tion of the experiment. BrdU incorporation into nuclei was determined by 
  immunoﬂ  uorescence microscopy. *, P < 0.01; **, P < 0.001. (C) Quiescent 
human SMCs were stimulated with 10% FBS in the presence or absence of 
200 μg/ml HMW-HA for 24 h. The cells were then stained with ﬂ  uorescein-
phalloidin and antivinculin. FBS-stimulated BrdU incorporation was inhibited 
54% by HMW-HA in this experiment. Bars, 20 μm. ANTIMITOGENESIS BY HYALURONAN • KOTHAPALLI ET AL. 537
We explored the mechanism underlying the CD44-
 dependent antimitogenic effect of HMW-HA by examining hyper-
phosphorylation of the Rb protein and induction of cyclin A, 
which are two cell cycle events that are closely linked to the 
completion of G1 phase and entry into S phase. HMW-HA 
blocked the mitogen-dependent hyperphosphorylation of Rb 
(shown by the gel shift; Fig. 2 A). Rb hyperphosphorylation re-
sults in the release of activator E2Fs and E2F-dependent gene 
transcription, and cyclin A is one of the E2F-regulated genes. 
Indeed, cyclin A promoter activity was inhibited by HMW-HA 
(Fig. 2 B). Moreover, the expression of human papillomavirus 
E7, which inactivates pocket proteins and results in E2F re-
lease, rescued cyclin A promoter activity in HMW-HA–treated 
SMCs (Fig. 2 B), demonstrating that the inhibitory effect of 
HMW-HA on the cyclin A promoter is directly related to its 
  effect on pocket protein phosphorylation. Consistent with its 
effect on the cyclin A promoter, HMW-HA inhibited the 
  mitogen-dependent induction of cyclin A mRNA (Fig. 2 C) and 
protein (Fig. 3 A).
HMW-HA inhibits mitogen-dependent 
induction of the cyclin D1 and Skp2 genes
Cyclin D1–cdk4/6 and cyclin E–cdk2 are the G1-phase cdk com-
plexes that are thought to control pocket protein phosphorylation. 
As discussed above (see Introduction), the rate-limiting step 
for the activation of these kinases is the mitogen-dependent 
  induction of cyclin D1 (leading to active cyclin D–cdk4/6) 
and the depletion of cyclin/cdk2-bound p27 (leading to active 
  cyclin E–cdk2). A time-course analysis showed that HMW-HA 
blocked both the mitogen-dependent induction of cyclin D1 
and the mitogen-dependent down-regulation of p27 (Fig. 3 A). 
Cyclin D1 mRNA levels were inhibited by HMW-HA (Fig. 3 B), 
and the time course of this effect was similar to that seen for 
  cyclin D1 protein (Fig. 3 A). In contrast, HMW-HA did not affect 
the levels of p27 mRNA (Fig. 3 C), indicating that its effect on 
p27 protein levels was likely posttranscriptional. These effects 
are selective because the mitogen-dependent changes in G1-phase 
p21 levels were unaffected by HMW-HA (Fig. 3 A).
The levels of p27 are typically controlled by ubiquitin-
mediated degradation, and a major ubiquitin ligase responsible 
for degrading p27 is the multimeric complex called SCF
Skp2 
(Carrano et al., 1999; DeSalle and Pagano, 2001; Philipp-
  Staheli et al., 2001; Cardozo and Pagano, 2004). Mitogenic 
stimuli regulate the activity of SCF
Skp2, at least in large part, by 
controlling the expression of Skp2 (Pagano, 2004). We studied 
the effect of HMW-HA on Skp2 gene expression and found 
that the mitogen-dependent induction of Skp2 mRNA and 
  protein were strongly inhibited by HMW-HA (Fig. 3 D). 
Figure 2.  Pocket protein–dependent effects of HMW-HA on cyclin A gene 
transcription. Quiescent human vascular SMCs (G0) were stimulated with 
10% FBS for the selected times in the absence (control, C) or presence of 
200 μg/ml HMW-HA. (A) The cells were collected, lysed, and immuno-
blotted for Rb and focal adhesion kinase (FAK; loading control). Top and 
bottom arrows indicate the positions of hyper- and hypophosphorylated 
Rb, respectively. Quantiﬁ   cation of Rb gel shifts from four independent 
  experiments indicated that Rb phosphorylation after FBS stimulation 
(18–24 h) was 54 and 28% in the absence and presence of HMW-HA, 
respectively. (B) Human SMCs were cotransfected with plasmids encoding 
the cyclin A promoter-driving luciferase, empty vector or E7, and Renilla 
luciferase. The transfected cells were serum starved for 24 h and stimulated 
with 10% FBS. Cyclin A promoter activity was determined in the absence 
or presence of HMW-HA and E7. Cyclin A promoter-luciferase activity is 
normalized to Renilla luciferase activity. *, P < 0.01. (C) Quiescent (G0) 
human SMCs were stimulated with 10% FBS for 24 h. Total RNA was 
  isolated and analyzed by QPCR for cyclin A mRNA and 18S rRNA. Cyclin 
A mRNA expression is normalized to 18S rRNA. *, P < 0.001. Error 
bars represent SD. 
Table I. HA inhibits S-phase entry in human and mouse SMCs
Cell cycle phase Percentage
mSMC hSMC
Serum starved
 G0/G1 91 84
 S3 6
 G2/M 5 3
FBS (24 h)
 G0/G1 59 84
 S1 8 1 1
 G2/M 23 2
FBS (24 h) + HMW-HA
 G0/G1 89 94
 S4 3
 G2/M 3 3
Quiescent human SMCs (hSMCs) and mouse SMCs (mSMCs) were stimulated 
with 10% FBS for 24 h in the absence or presence of 200 μg/ml HMW-HA. 
Cells were collected, washed with PBS, ﬁ   xed in ethanol, stained with pro-
pidium iodide, and analyzed for DNA content by ﬂ  ow cytometry using standard 
procedures. Results show the percentages of cells in different stages of the 
cell cycle.JCB • VOLUME 176 • NUMBER 4 • 2007  538
The   combined results in Fig. 3 show that the antimitogenic 
  effect of HMW-HA is associated with an inhibition of both 
  cyclin D1 and Skp2 gene expression. Many studies have indi-
cated that both of these effects would be expected to inhibit 
G1-phase progression and S-phase entry. Indeed, the ectopic 
expression of either cyclin D1 or Skp2 was suffi  cient to over-
come the anti  mitogenic effect of HMW-HA on S-phase entry 
in vascular SMCs (Fig. 4 A).
Cyclin D1 is the primary target of HMW-HA
Recent studies indicate that Skp2 is an E2F target (Markey 
et al., 2002; Vernell et al., 2003; Zhang and Wang, 2006). This 
fi  nding raised the possibility that cyclin D1 is the primary target 
of HMW-HA and that the inhibition of Skp2 seen in SMCs 
treated with HMW-HA is a secondary consequence of decreased 
cyclin D1–cdk4/6 activity, decreased Rb phosphorylation, and 
decreased E2F release (see Introduction). To determine whether 
the effects of HMW-HA on cyclin D1 and Skp2 are related 
or independent, we asked whether the ectopic expression of 
  cyclin D1 would override the effect of HMW-HA on Skp2 gene 
expression. We found that the ectopic expression of cyclin D1 
(Fig. 4 B) rescued the expression of Skp2 mRNA in HMW-HA–
treated SMCs (Fig. 4 C). In contrast, the ectopic expression of 
Skp2 (Fig. 4 B) was unable to rescue cyclin D1 gene expression 
in the presence of HMW-HA (Fig. 4 D). The results from these 
experiments indicate that the primary antimitogenic effect of 
HMW-HA is on the expression of cyclin D1 and that the effect 
of HMW-HA on Skp2 is likely a secondary consequence of in-
hibiting cyclin D1–cdk4/6 complex formation, Rb phosphory-
lation, and E2F release.
Figure 3.  Subcellular effects of HMW-HA on G1-phase 
cdks. Quiescent human vascular SMCs (G0) were stimu-
lated with 10% FBS for the selected times in the absence 
(control, C) or presence of 200 μg/ml HMW-HA. (A) Col-
lected cells were lysed and immunoblotted for cyclin D1, 
p27, p21, cyclin A, and cdk4 (loading control). (B and C) 
Total RNA was isolated from SMCs and analyzed by 
QPCR for cyclin D1 mRNA, p27 mRNA, and 18S rRNA, 
and the levels of cyclin D1 (B) and p27 mRNA (C) were 
normalized to 18S rRNA. *, P < 0.01. (D) Quiescent hu-
man SMCs were stimulated with 10% FBS for 24 h in the 
absence or presence of 200 μg/ml HMW-HA. Total RNA 
was isolated from the SMCs and analyzed by QPCR for 
Skp2 mRNA and 18S rRNA. Skp2 mRNA expression is 
plotted relative to 18S rRNA. *, P < 0.001. Collected 
cells were also lysed and immunoblotted for Skp2 and 
cdk4 (inset). Error bars represent SD. 
Figure 4.  Cyclin D1 is the proximal target of 
HMW-HA. Human vascular SMCs infected with 
adenoviruses encoding lacZ (Ad-lacZ), cyclin 
D1 (Ad-D1), or Skp2 (Ad-Skp2) were serum 
starved and stimulated with 10% FBS-DME in the 
absence (control, C) or presence of 200 μg/ml 
HMW-HA. (A) The cultures were incubated 
for 24 h in the presence of BrdU, and BrdU 
  incorporation into nuclei was determined by 
immunoﬂ  uorescence microscopy. *, P < 0.01. 
(B) Collected cells were lysed and immuno-
blotted for cyclin D1 and cdk4 (loading 
control) or Skp2 and focal adhesion kinase 
(FAK;   loading control). The thin vertical spaces 
between the Ad-lacZ, Ad-D1, and Ad-Skp2 im-
ages indicate reordering of these image blocks 
from the scanned gel. (C and D) Total RNA 
was isolated from the SMCs and used to deter-
mine the levels of Skp2 mRNA or cyclin D1 
mRNA. The expression of cyclin D1 and Skp2 
mRNAs was normalized to 18S rRNA and 
plotted relative to their expression levels in 
cells infected with the lacZ adenovirus. *, P < 
0.005. Error bars represent SD. ANTIMITOGENESIS BY HYALURONAN • KOTHAPALLI ET AL. 539
Conserved effects of HA and CD44 
on cyclin D1, Skp2, and cyclin A levels 
in primary mouse SMCs and ﬁ  broblasts
HMW-HA is antimitogenic in early passage mouse vascular 
SMCs, as determined by both BrdU incorporation (Fig. 5 A) 
and fl  ow cytometry (Table I). Moreover, HMW-HA inhibits the 
mitogen-dependent induction of cyclin D1, Skp2, and cyclin A 
mRNAs (Fig. 5 B). The down-regulation of p27 was partially 
inhibited by HMW-HA in wild-type mouse SMCs (Fig. 5 C) 
without comparable change in the level of p27 mRNA (Fig. 5 B). 
Cyclin D1 and Skp2 proteins levels were also inhibited by 
HMW-HA (Fig. 5 C). All of these effects recapitulated the re-
sults we obtained in human SMCs.
The use of mouse SMCs allowed us to compare the effect 
of HMW-HA in wild-type and CD44-null cells. We found that 
none of the aforementioned HMW-HA effects were recapitu-
lated in vascular SMCs isolated from CD44-null mice (Fig. 5, 
A–C). Thus, CD44 is the major HA receptor mediating the 
  antimitogenic effects of HMW-HA in mouse vascular SMCs. 
Similar CD44-dependent effects of HMW-HA were detected in 
early passage mouse lung fi  broblasts (Table II). Moreover, the 
ectopic expression of cyclin D1 overcame the inhibitory effects 
of HMW-HA on Skp2 mRNA, cyclin A mRNA, and S-phase 
entry in mouse embryonic fi  broblasts (MEFs; Table III). Con-
sistent with these results, HA binding to CD44 was detected in 
both primary mouse SMCs and fi  broblasts (Fig. 5 D). Thus, the 
antimitogenic effects of HMW-HA and the critical role of CD44 
in these effects are well conserved in mouse and human vascular 
SMCs as well as in mouse embryonic and lung fi  broblasts.
Antimitogenic effects of CD44 on SMC 
mitogenesis in vivo
We then investigated whether CD44 regulates SMC mitogenesis 
in vivo. Aortae were isolated from 20-wk-old male wild-type 
and CD44-null mice, total RNA was isolated, and real-time 
quantitative PCR (QPCR) was performed to compare the levels 
of cyclin D1, Skp2, and cyclin A mRNAs. All three of these 
transcripts were increased in the aortae lacking CD44 (Fig. 6 A), 
Figure 5.  HMW-HA inhibits cyclin D1, Skp2, and cyclin A 
expression in wild-type mouse vascular SMCs. Quies-
cent (G0) mouse vascular SMCs from wild-type (WT) or 
CD44-null mice were stimulated with 10% FBS for the se-
lected time intervals in the absence (control, C) or pres-
ence of 200 μg/ml HMW-HA. (A) Cells were incubated 
for 24 h in the presence of BrdU, and BrdU incorpora-
tion into nuclei was determined by immunoﬂ  uorescence 
microscopy. *, P < 0.002. (B) Cells were collected, lysed, 
and analyzed by QPCR for cyclin D1, Skp2, cyclin A, 
and p27 mRNAs as well as for 18S rRNA. Results for 
each mRNA are plotted relative to 18S rRNA. *, P < 0.01. 
(C) Collected cells from identical experiments were ana-
lyzed by Western blotting for either cyclin D1, Skp2, and 
cdk4 (loading control) or p27 and cdk4 (loading control). 
(D) Primary MEFs and vascular SMCs were lysed and 
  immunoblotted for CD44. HA binding to CD44 was deter-
mined using FITC-conjugated HA in the absence and pre-
sence of CD44-neutralizing antibody (KM81). Error bars 
represent SD.
Table II. Effects of HMW-HA on wild-type and CD44-null mouse lung ﬁ  broblasts
CD44 WT MLF CD44-null MLF
−HMW-HA +HMW-HA −HMW-HA + HMW-HA
Cyclin D1 mRNA 0.37 0.07 0.39 0.36
Skp2 mRNA 0.27 0.04 0.26 0.24
Cyclin A mRNA 0.24 0.07 0.25 0.24
BrdU-incorporated cells (%) 43 21 42 38
Early passage adult mouse lung ﬁ  broblasts (MLFs) from wild-type (WT) or CD44-null mice were serum starved and stimulated with 10% FBS for 24 h in the absence (−) 
or presence (+) of 200 μg/ml HMW-HA. Total RNA was isolated, and QPCR was used to measure the levels of cyclin D1 mRNA, Skp2 mRNA, cyclin A mRNA, and 
18S rRNA. The expression of cyclin D1, Skp2, and cyclin A mRNAs were normalized to 18S rRNA. Results show the means of duplicate PCR reactions. SDs ranged 
from 0.001 to 0.01. BrdU incorporation was determined 24 h after stimulation with 10% FBS.JCB • VOLUME 176 • NUMBER 4 • 2007  540
with fold increases of 6 ± 2.7 for cyclin D1, 8 ± 2.1 for 
Skp2, and 7.5 ± 1.5 for cyclin A mRNAs (mean ± SD; repre-
sents data from two pools of four aortae for a total of eight 
aortae). Cyclin D1 and Skp2 mRNA levels were also increased 
(relative to wild-type controls) in CD44-null aortic arches and 
thoracic aortae from 10-wk-old female mice (Fig. S1, available 
at http://www.jcb.org/cgi/content/full/jcb.200611058/DC1), in-
dicating that these effects of CD44 are independent of age and 
gender. Note that the mRNA levels of CD31 (platelet endothe-
lial cell adhesion molecule; endothelial marker), CD68 (macro-
phage marker), and smooth muscle actin (smooth muscle 
marker) were similar in the wild-type and CD44-null aortae, 
with smooth muscle actin being the most abundant as expected 
(Fig. 6 B). Thus, these CD44-dependent changes in cyclin D1, 
Skp2, and cyclin A mRNAs are not caused by alterations in the 
cellular composition of the samples. We conclude that in the 
uninjured artery, the binding of HMW-HA to CD44 exerts a 
negative effect on the cell cycle that helps to maintain arterial 
SMCs in a quiescent state in vivo.
Despite the increased expression of cyclin A mRNA, aor-
tae isolated from CD44-null mice did not show gross evidence 
of SMC hyperplasia as assessed by morphometric analysis 
of hematoxylin and eosin– (Fig. 6 C, medial layer) or elastin 
(not depicted) -stained aortic sections. Thus, the increased ex-
pression of cyclin A mRNA in the CD44-null artery is appar-
ently counterbalanced in vivo to maintain arterial homeostasis 
in the uninjured artery.
It is well established that intimal endothelial cells release 
potent antimitogens for underlying medial SMCs (see Discus-
sion), and we reasoned that the release of these intimal antimi-
togens might be responsible for the absence of cell proliferation 
in resting CD44-null arteries (Fig. 6 C). Therefore, we denuded 
the endothelial layer of the femoral artery in wild-type and 
CD44-null mice by performing fi  ne wire injuries. Although the 
intact endothelium is eventually restored after injury, the tran-
sient denudation results in proliferation of the medial SMCs, 
which can be detected by an increased intimal/medial ratio and 
BrdU labeling. We asked whether the loss of CD44 increased 
SMC proliferation in this injury setting.
Femoral arteries were isolated, fi   xed, and stained for 
  elastin 14 d after arterial injury. The internal elastic lamina 
was restored in both wild-type and CD44-null mice (Fig. 7 A). 
However, neointimal thickening was clearly increased in the 
CD44-null mice relative to controls (Fig. 7 A). This proliferative 
effect was quantifi  ed by morphometric analysis, which showed 
an approximately twofold increase in the neointimal/medial 
Figure 6.  CD44 regulates the expression of cyclin D1, 
Skp2, and cyclin A in the aorta. (A and B) Total RNA was 
isolated twice from pooled, cleaned aortae of four 20-wk-
old male CD44 wild-type (black bars) and CD44-null 
(white bars) mice for a total of eight mice/genotype. 
cDNA was synthesized for each isolation, and QPCR was 
performed on a cDNA aliquot for cyclin D1, Skp2, cyclin A 
mRNAs, and 18S rRNA (A) or CD31, CD68, smooth 
  muscle actin (SMA) mRNAs, and 18S rRNA (B). The ex-
pression of cyclin D1, Skp2, cyclin A, CD31, CD68, and 
smooth muscle actin mRNAs are plotted relative to 18S 
rRNA. *, P < 0.003. Error bars represent SD. (C) Tho-
racic aortae were isolated from 20-wk-old male wild-type 
(WT) and CD44-null mice. The intima and adventitia were 
not removed before the tissues were ﬁ  xed, embedded in 
parafﬁ  n, sliced in cross section, and stained with hema-
toxylin and eosin. Genotypes were conﬁ  rmed by PCR. 
A, adventitia; M, media; L, lumen. Bars, 210 μm. 
Table III. Cyclin D1 is the primary target of HMW-HA in early passage MEFs
Ad-lacZ Ad-D1
−HMW-HA +HMW-HA −HMW-HA +HMW-HA
Cyclin D1 mRNA 0.21 0.08 1.23 1.16
Skp2 mRNA 0.08 0.02 0.95 0.91
Cyclin A mRNA 0.11 0.01 0.22 0.24
BrdU-incorporated cells (%) 51 13 53 51
Near-conﬂ  uent cultures of early passage MEFs were infected with adenoviruses encoding lacZ (Ad-lacZ) or cyclin D1 (Ad-D1) and were serum starved. Western 
  blotting (unpublished data) conﬁ  rmed overexpression of the proteins. The infected starved cells were incubated with 10% FBS and BrdU for 24 h in the absence (−) 
or presence (+) of 200 μg/ml HMW-HA. Total RNA was isolated, and QPCR was used to measure the levels of cyclin D1 mRNA, Skp2 mRNA, cyclin A mRNA, and 
18S rRNA. The expression of cyclin D1, Skp2, and cyclin A mRNAs were normalized to 18S rRNA. QPCR results show the means of duplicate PCR reactions. SDs 
ranged from 0.001 to 0.007. BrdU incorporation was determined 24 h after stimulation with 10% FBS.ANTIMITOGENESIS BY HYALURONAN • KOTHAPALLI ET AL. 541
ratio (Fig. 7 B). A similar increase was seen in the number of 
BrdU-positive neointimal nuclei (Fig. 7 B). In contrast, neither 
wild-type nor CD44-null mice showed evidence of neointimal 
formation (Fig. 7 C) or SMC proliferation (not depicted) in sham-
operated uninjured femoral arteries.
Discussion
Vascular SMCs synthesize HMW-HA, which is then released 
and deposited in the SMC matrix, where it can bind in an auto-
crine and paracrine fashion to the CD44 expressed on the SMC 
surface. We previously reported that the binding of HMW-HA 
to CD44 is antimitogenic for vascular SMCs (Cuff et al., 2001). 
Similarly, others have shown that HA inhibits PDGF-stimulated 
receptor activation and proliferation (Papakonstantinou et al., 
1998; Li et al., 2006) and that the ectopic expression of HA 
  synthases (which leads to the production of HMW-HA) inhibits 
the proliferation of arterial SMCs (Wilkinson, 2006).
The data presented here provide a mechanism for the anti-
mitogenic effect of HMW-HA, show that this mechanism oper-
ates in vivo, and lead us to propose that the interaction between 
HA and CD44 on SMCs contributes to the maintenance of SMC 
quiescence in the healthy artery. First, our experiments with early 
passage human and mouse SMCs in culture show that HMW-HA 
can repress the mitogen-dependent induction of cyclin D1 and 
that this effect is associated with an inhibition of downstream 
cell cycle events such as Rb phosphorylation, Skp2 expression, 
p27 down-regulation, and cyclin A expression. Second, we show 
that the inhibitory effect of HMW-HA on cyclin D1 is causally 
related to its antimitogenic effect because ectopic cyclin D1 
  expression rescues S-phase entry in HMW-HA–treated cells.
In agreement with our results using vascular SMCs in 
  culture, our data in vivo show that the expression of cyclin D1, 
Skp2, and cyclin A mRNAs is increased in the aortae of CD44-
null mice, a result that strongly supports the physiological rele-
vance of the HMW-HA effects we and others (Wilkinson, 2006) 
detect in vitro. The increased expression of cyclin A is typically 
associated with entry and progression through S phase, but 
  resting aortae from CD44-null mice showed no gross evidence 
of SMC hyperplasia as compared with wild-type controls. There 
are several possible explanations for this result. First, increased 
proliferation of CD44-null SMCs could have been offset by in-
creased turnover (Lakshman et al., 2005). Second, the lack of 
proliferation in CD44-null arterial SMCs could have refl  ected 
a compensatory change that occurs during development in the ab-
sence of CD44. Third, the intimal endothelium, which is known 
to release potent antimitogens such as TGF-β, nitric oxide, and 
prostacyclin (Cucina et al., 1998; Mombouli and Vanhoutte, 
1999; Tanner et al., 2000), could have been obscuring the effect 
of CD44 deletion. Our ability to document the enhanced prolif-
eration of CD44-null SMCs after arterial injury strongly supports 
the idea that the release of antimitogens from intact endothelium 
prevents the proliferation of medial SMCs in resting arteries of 
CD44-null mice.
HMW-HA is widely distributed in ECM in vivo, and our 
data indicate that the presence of HMW-HA provides an active, 
repressive signal that cooperates with intimal antimitogens to 
maintain vascular SMCs in a resting state. Our results also sug-
gest that the degradation of HMW-HA to lower molecular 
weight forms, which is thought to occur at sites of arterial injury 
and infl  ammation (Noble, 2002), would eliminate the antimito-
genic effects of HMW-HA and CD44. Additionally, the lower 
Figure 7.  Increased neointima formation and BrdU incorporation after vascular injury in CD44-null mice. (A) Injured femoral arteries from wild-type and 
CD44-null mice were perfusion ﬁ  xed, parafﬁ  n embedded, and sectioned before being stained for elastin. Boxes indicate the regions of the aortae that are 
shown at twofold higher magniﬁ  cation. Arrows indicate sites of neointima formation. (B) Intimal/medial ratios and the number of BrdU-positive nuclei in 
  injured femoral arteries of wild-type and CD44-null mice. n = 5 per genotype. P = 0.02 for intimal/medial ratios, and P = 0.06 for BrdU as determined 
  using a one-tailed t test. Horizontal bars indicate mean values. (C) The sham-operated control arteries from the mice in A were stained for elastin. JCB • VOLUME 176 • NUMBER 4 • 2007  542
molecular forms of HA that may accumulate as a result of in-
fl  ammation can exert a positive effect on G1-phase progression 
in and of themselves (Cuff et al., 2001; Nasreen et al., 2002; 
Huang et al., 2003). Together, the loss of HMW-HA and the ap-
pearance of its lower molecular weight isoforms could contri-
bute to modulation of SMCs to the proliferative phenotype 
characteristic of vascular injury. Thus, we propose that the 
maintenance or degradation of HMW-HA can act as a rheostat, 
regulating the extent of growth factor– and ECM-dependent 
SMC proliferation.
Much of our study focused on the actions of HMW-HA on 
vascular SMCs so that we could assess molecular effects both in 
cultured cells and in vivo. However, we also show that HMW-HA 
is a potent antimitogenic factor for both lung and embryonic 
 fi broblasts. In both primary SMCs and fi  broblasts, the antimito-
genic effect of HMW-HA is mediated by CD44. Moreover, 
HMW-HA similarly affects cyclin D1, Skp2, and p27 in SMCs 
and fi  broblasts, and cyclin D1 is the primary target in both cell 
types. The broad distribution of HMW-HA and the expres-
sion of CD44 indicates that this ligand–receptor system is 
likely to have an antimitogenic effect on multiple mesenchymal 
cell types.
Materials and methods
Cell culture
Primary human vascular SMCs isolated from human aortae were obtained 
from Cascade Biologics, Inc., maintained as described previously (Motamed 
et al., 2002), and used between passage 2 and 9. Near-conﬂ   uent 
  monolayers were G0 synchronized by incubation in 1 mg/ml of serum-free 
DME containing heat-inactivated fatty acid–free BSA (DME-BSA) for 48 h. 
14 mg/ml of a concentrated HMW-HA solution (Healon GV; GE Health-
care) was diluted to 200 μg/ml with DME and 10% FBS. The medium con-
taining HMW-HA was then directly added to the quiescent cells. In some 
experiments, HMW-HA was supplemented with 1 μg/ml Polymyxin B 
(Sigma-Aldrich) to control for potential lipopolysaccharide contamination. 
As expected from our use of patient- grade HA, the addition of Polymyxin B 
had no effect on any of the results. Primary mouse vascular SMCs were 
isolated from aortae of wild-type and CD44-null C57BL/6 mice, main-
tained as described previously (Cuff et al., 2001), and used at passages 
2–5. The adhesion and morphology of the wild-type and CD44-null SMCs 
were similar under the conditions of our experiments. Primary lung ﬁ  bro-
blasts were isolated from 8–12-wk-old wild-type and CD44-null C57BL/6 
mice. Primary MEFs were isolated from embryonic day 12.5 C57BL/6 
embryos. The explanted mouse ﬁ   broblasts were maintained in DME 
  containing 10% FBS and used at passage 2–5. Each of the ﬁ  broblast cell 
types was serum starved by incubation in DME-BSA for 48 h. To control for 
speciﬁ  city, we tested the effect of exogenous heparan sulfate and found 
that it did not inhibit BrdU incorporation in serum-stimulated mouse or 
  human SMCs.
Adenoviral infections and transfections
For adenoviral infections, 3 × 10
5 human vascular SMCs or 6 × 10
5 MEFs 
in 10% FBS-DME were seeded overnight in 100-mm dishes and incubated 
in DME-BSA for 12 h. Adenoviruses encoding lacZ, cyclin D1 (a gift from 
J. Albrecht, Hennepin County Medical Center, Minneapolis, MN), or Skp2 
(a gift from K. Nakayama, Kyushu University, Fukuoka, Japan) were di-
rectly added to the near-conﬂ  uent cultures and incubated overnight. The 
medium was then replaced with fresh DME-BSA, and the cultures were in-
cubated for an additional 24 h. The infected starved cells were washed 
once with serum-free DME before being directly stimulated with 10% FBS 
in the presence or absence of 200 μg/ml HMW-HA. The adenovirally ex-
pressed cDNAs were efﬁ  ciently expressed in the serum-stimulated but not 
serum-starved cells.
Cyclin A promoter-luciferase assays were performed after transient 
transfection of near-conﬂ  uent SMCs (5 × 10
4 cells in 35-mm dishes) as 
  described previously (Kothapalli et al., 2003) using 1 μg p434/cyclin A 
promoter-luciferase expression vector (bases −270–164), 0.01 μg Renilla 
luciferase vector, and 1 μg of either empty vector or an E7 expression 
  vector. Cyclin A promoter-driven luciferase activity and Renilla luciferase 
activities were measured twice for each sample, and the mean ± SD 
was plotted.
Immunoblotting
Human or mouse vascular SMCs were seeded (3 × 10
5 cells per 100-mm 
dish), incubated overnight, serum starved, and stimulated with 10% FBS in 
the absence or presence of HMW-HA. The cells were then collected and 
lysed as described previously (Welsh et al., 2001). Total protein concentra-
tion was determined by Coomassie binding (Bio-Rad Laboratories). Equal 
amounts of protein (50–100 μg) were resolved on reducing SDS mini-gels 
and analyzed by immunoblotting using antibodies speciﬁ  c for the following 
proteins: cyclin D1, p21, cdk4 (all were obtained from Santa Cruz 
  Biotechnology, Inc.), p27 (BD Transduction Laboratories), Skp2 (Zymed 
Laboratories), Rb (Zymed Laboratories), and COX-1 (Cayman Chemical). 
Rabbit polyclonal cyclin A antibody was prepared in our laboratory. The 
resolved proteins were detected using ECL (GE Healthcare). Autoradio-
grams were digitized by scanning, and ﬁ  gures were assembled using Photo-
shop (Adobe). The small numbers on the left side of each blot represent 
typical migration positions of molecular weight standards (Mr × 10
−3).
Immunoﬂ  uorescence microscopy
Human vascular SMCs, mouse vascular SMCs, mouse lung ﬁ  broblasts, and 
MEFs (70–80% conﬂ  uent) were seeded on dishes containing autoclaved 
glass coverslips, serum starved, and stimulated with 10% FBS in the ab-
sence or presence of HMW-HA. In some experiments, 50 μg/ml of a species-
speciﬁ  c blocking antibody to human CD44 (5F12; Liao et al., 1993) or 
an irrelevant isotype-matched antibody was added to the human SMCs 
at the time of FBS stimulation. Fixed cells were analyzed at room tempera-
ture by immunoﬂ   uorescence for the incorporation of BrdU as described 
previously (Kothapalli et al., 2003) using AlexaFluor594-conjugated don-
key anti–sheep secondary antibody to visualize BrdU staining. The percent-
age of BrdU-positive cells was assessed by epiﬂ  uorescence microscopy by 
counting the number of BrdU-positive nuclei relative to the total number of 
DAPI-stained nuclei and typically counting  150 nuclei in several separate 
ﬁ   elds of view per sample. Stress ﬁ   bers were stained using ﬂ  uorescein-
phalloidin as described previously (Welsh et al., 2001). Focal adhesions 
were immunostained using antivinculin (Sigma Aldrich) and AlexaFluor594-
conjugated goat anti–mouse secondary antibody. A representative result 
is shown for each ﬁ   gure. Images were acquired using a microscope 
(Eclipse 80i; Nikon), 20× 0.45 NA plan Fluor (ELWD; Nikon) and 
40× 0.7 NA PL Fluotar (Leitz) objectives, a digital camera (C4742-95; 
  Hamamatsu), and a camera controller. Images were converted to TIFF ﬁ  les 
using Openlab imaging software (Improvision) and were assembled using 
Photoshop (Adobe).
Quantitative real-time RT-PCR
Quiescent human or mouse vascular SMCs were stimulated with 10% 
FBS in 100-mm dishes in the absence or presence of HMW-HA. The 
cells were washed once with cold PBS, scraped, and collected in 0.5 ml 
of fresh PBS. Total RNA was then extracted from the collected cell 
pellet using 1 ml TRIzol reagent (Invitrogen) followed by reverse tran-
scription using  100 ng of total RNA as described previously (Stewart 
et al., 2004). An aliquot (10%) of the cDNA was subjected to PCR 
using TaqMan Universal PCR Master Mix (Applied Biosystems; Stewart 
et al., 2004). Real-time PCR for human cyclin D1 was performed using 
900 nM of forward primer 5′-T  G  T  T  C  G  T  G  G  C  C  T  C  T  A  A  G  A  T  G  A  A  G  -3′, 900 nM 
of reverse primer 5′-A  G  G  T  T  C  C  A  C  T  T  G  A  G  C  T  T  G  T  T  C  A  C  -3′, and 250 nM 
of probe 5′-6FAM-A  G  C  A  G  C  T  C  C  A  T  T  T  G  C  A  G  C  A  G  C  T  C  C  T  -TAMRA-3′. 
Real-time PCR for mouse cyclin D1 was performed using 900 nM of for-
ward primer 5′-T  G  C  C  A  T  C  C  A  T  G  C  G  G  A  A  A  -3′, 900 nM of reverse primer 
5′-A  G  C  G  G  G  A  A  G  A  A  C  T  C  C  T  C  T  T  C  -3′, and 250 nM of probe 5′-6FAM-C  T  C-
A  C  A  G  A  C  C  T  C  C  A  G  C  A  T  -MGBNFQ-3′. TaqMan gene expression assays 
(Applied Biosystems) were used to detect human Skp2 mRNA (assay ID 
Hs00261857_m1), human p27 (assay ID Hs00153277_m1), human 
  cyclin A (assay ID Hs00171105_m1), mouse Skp2 (Stewart et al., 2004), 
mouse p27 (assay ID Mm00438167_g1), and mouse cyclin A (assay ID 
Mm00438064_m1). To detect both human and mouse 18S rRNA, we 
used TaqMan gene expression assay ID Hs99999901_s1 or 150 nM of 
forward primer 5′-C  C  T  G  G  T  T  G  A  T  C  C  T  G  C  C  A  G  T  A  G  -3′, 150 nM of reverse 
primer 5′-C  C  G  T  G  C  G  T  A  C  T  T  A  G  A  C  A  T  G  C  A  -3′, and 100 nM of probe VIC-
T  G  C  T  T  G  T  C  T  C  A  A  A  G  A  T  T  A  -MGB-NFQ. QPCR was performed as described 
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Each sample was analyzed in duplicate PCR reactions, and mRNA 
  expression was quantiﬁ  ed using ABI PRISM 7000 SDS software (Applied 
Biosystems). Mean quantities and SD were calculated from duplicate 
PCR reactions.
To perform QPCR on mouse arteries, aortae (excluding the abdominal 
aorta) were isolated from eight 20-wk-old male wild-type and CD44-null 
mice, both on the C57BL/6 background. After extensive cleaning to 
  remove the adventitia and intima, the aortae were stabilized by submerging 
in RNALater (QIAGEN). Before isolating the total RNA, the aortae were 
weighed, and  30 mg of aortic tissue (four aortae) were manually homo-
genized and treated with 20 mg/ml proteinase K (Roche Diagnostics) 
at 55°C for 10 m. The homogenate was clariﬁ  ed by centrifugation, and 
  total RNA was isolated from the supernatant using RNeasy mini columns 
(QIAGEN). Reverse transcription and QPCR were performed as described 
in the previous paragraph using 20% of the reverse transcription reaction 
and primers and probes to mouse cyclin D1 mRNA, Skp2 mRNA, cyclin 
A mRNA, and 18S rRNA. Primers for mouse CD31 mRNA (forward 5′-C  T  G-
C  A  G  G  C  A  T  C  G  G  C  A  A  A  -3′ and reverse 5′-G  C  A  T  T  T  C  G  C  A  C  A  C  C  T  G  G  A  T  -3′), 
mouse CD68 mRNA (forward 5′-T  G  G  A  C  A  G  C  T  T  A  C  C  T  T  T  G  G  A  T  T  C  A  -3′ 
and reverse 5′-T  G  T  A  T  T  C  C  A  C  C  G  C  C  A  T  G  T  A  G  T  C  -3′), and mouse smooth 
muscle actin mRNA (forward 5′-C  C  A  G  A  G  C  A  A  G  A  G  A  G  G  G  A  T  C  C  T  -3′ and 
reverse 5′-T  G  T  C  G  T  C  C  C  A  G  T  T  G  G  T  G  A  T  G  -3′) were obtained from Sigma-
Genosys. The CD31, CD68, and smooth muscle actin mRNAs were analyzed 
using 1 μM of forward and reverse primers and SYBR Green PCR Master 
Mix (Applied Biosystems).
CD44 protein expression and HA binding
Near-conﬂ  uent early passage primary MEFs or mouse vascular SMCs 
were lysed using 1.5% NP-40 in PBS containing a protease inhibitor cocktail 
(0.2 U/ml aprotinin and 0.2 mg/ml PMSF). Equal amounts of total protein 
were resolved on 7.5% SDS gels under nonreducing conditions and trans-
ferred to polyvinylidene diﬂ  uoride membranes. Proteins were analyzed by 
immunoblotting with an antibody (KM81) that detects total mouse CD44. 
HA binding to CD44 was detected by incubating the polyvinylidene diﬂ  uoride 
membranes with FITC-HA in the presence or absence of blocking anti-CD44 
(KM81; Miyake et al., 1990). Total CD44 levels and HA binding were visu-
alized by ECL using HRP-conjugated secondary anti–rat IgG (Jackson Immuno-
Research Laboratories) and anti-FITC (Roche Diagnostics), respectively.
Femoral artery injury
The intimal layer of the left femoral artery was denuded in anesthetized 
wild-type and CD44-null C57BL/6 male mice (24–28 wk and 30–32 g) by 
insertion of a 0.36-mm angioplasty guide wire (Advanced Cardiovascular 
Systems) largely as described previously (Roque et al., 2000) except that 
the anesthesia was avertin, and the guide wire was kept in the femoral 
  artery for 3 min. The right femoral artery was sham operated and used 
as control. The mice were maintained on a standard diet and water ad 
  libitum. 14 d after injury, the mice were anesthetized, perfused with 0.9% 
NaCl (by placement of a 22-gauge needle in the left ventricle), and per-
fusion ﬁ  xed in situ by infusion with Prefer ﬁ  xative (Anatech Ltd.). In some 
  experiments, the mice received four injections of 50 mg/kg BrdU intra-
peritoneally 12, 24, 48, and 72 h before perfusion. Both right and left 
femoral arteries were harvested and embedded in parafﬁ  n. All procedures 
were approved and animal husbandry was overseen by the Institutional 
Animal Care and Usage Committee of the University of Pennsylvania.
5-μm cross sections were made through the injured part of the iso-
lated femoral artery, and identical cross sections were made in the sham-
operated arteries. Three sections corresponding to the peak injury region 
of each artery were processed for elastin staining using the Accustain Elastic 
Stain (Sigma-Aldrich). Adjacent sections were stained with BrdU Labeling 
and Detection Kit II (Roche Diagnostics) according to manufacturer’s in-
structions except that we ﬁ  rst performed HCl-trypsin antigen retrieval gener-
ally as described previously (Cheng et al., 2002), incubated the sections 
in NH4Cl, and blocked them with 20 mg/ml BSA in PBS. Images of the 
elastin- and anti-BrdU–stained sections were captured using a microscope 
(Eclipse 80i; Nikon), 10× 0.3 NA plan Fluor or 20× 0.45 NA plan Fluor 
objectives (Nikon), and a color camera (MicroPublisher 5.0 RTV; QImaging). 
Each of the elastin-stained sections were subjected to a morphometric 
  analysis with Openlab software (Improvision) to determine mean intimal 
and medial areas (Roque et al., 2000). The total number of BrdU-positive 
nuclei in a peak injury section was determined by visual counting of the 
captured image. Samples showing the highest and lowest injury responses 
for each genotype were removed from the analysis, and the remaining 
data were plotted using Prism software (GraphPad). Statistical analysis 
used the one-tailed unpaired t test.
Online supplemental material
Fig. S1 shows the effect of CD44 on cyclin D1 and Skp2 mRNA in female 
mice. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.200611058/DC1.
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